Coenzyme Q10

From another post I just wrote:

I read the recent studies, and was surprised they used oxidized CoQ10 vs reduced, which is absorbed multiple times better – and also focused on improved symptoms vs halting further symptoms, which I always read was the purpose of the Ubiquinol. Although, in the 2nd CoQ10 study, they did have good results in helping with symptoms, but the 3rd study didn’t bear that out. But I’m still confused as to the type of CoQ10 they selected.

My friend agreed to try this, but wants to wait until he finishes his CoQ10 standard drug store stuff – 100mg twice a day. The Ubiquinol should make a difference at 1200mg, per the 2nd CoQ10 study, especially since, not only is it a higher dosage, it is 3X+ better absorbed. Wish we didn’t have to wait.

Take CoQ10.

Even though CoQ10 failed to slow PD progression in this trial, it has neuroprotective effects and statin use lowers CoQ10.

My father had PD and I have many of the early symptoms like loss of smell, REM sleep disorder, and orthostatic hypotension. The CoQ10 takes away my OH symptoms so I no longer become dizzy when standing up quickly.

The expert discusses the potential of Coenzyme Q10 (CoQ10) as a treatment for Parkinson's disease. While a large study funded by the National Institutes of Health did not find evidence supporting its effectiveness, the expert suggests that the study's design might have overlooked certain factors. For example, about 30% of people with Parkinson's may have CoQ10 deficiency, and the study did not specifically target this group. The expert believes that future research should focus on identifying individuals who are most likely to benefit from CoQ10 supplementation.

The expert discusses the potential of Coenzyme Q10 (CoQ10) as a treatment for Parkinson's disease, noting that while a large phase 3 study showed negative results, earlier data suggested possible benefits. They highlight that 30% of people with Parkinson's may have CoQ10 deficiency, and question whether the study results were diluted by including participants who were not deficient. The expert also critiques the design of disease modification trials, suggesting that restricting access to dopamine in such studies may not be ideal. They advocate for more pragmatic study designs to better identify individuals who could benefit from interventions.

This study investigated whether high doses of Coenzyme Q10 (CoQ10), an antioxidant, could slow the progression of early-stage Parkinson's disease. It was a phase III randomized, placebo-controlled, double-blind clinical trial conducted at 67 sites in North America, involving 600 participants who were recently diagnosed with Parkinson's.

The study found that CoQ10, at doses of 1200 mg/day and 2400 mg/day, was safe and well-tolerated but did not provide any clinical benefit in slowing disease progression. Participants in both CoQ10 groups showed slightly worse trends in disease progression compared to the placebo group, as measured by changes in the Unified Parkinson's Disease Rating Scale (UPDRS).

For individuals with Parkinson's or their caregivers, this study suggests that CoQ10, despite being safe, is unlikely to slow the progression of the disease. This information can help guide treatment decisions and focus attention on other potential therapies.

This study is highly reliable as it was a phase III randomized controlled trial, which is a gold standard in clinical research. It was published in a reputable journal, JAMA Neurology, and involved a large sample size with rigorous methodology.

This study explored whether Coenzyme Q10 (CoQ10) is safe, well-tolerated, and effective in slowing the progression of Parkinson's disease (PD). It was conducted as a randomized, placebo-controlled trial with 80 participants who had early-stage PD and did not yet require treatment for their symptoms.

The study found that CoQ10 was safe and well-tolerated at doses up to 1200 mg per day. Participants taking the highest dose (1200 mg/day) experienced the least functional decline, as measured by the Unified Parkinson Disease Rating Scale (UPDRS), compared to those on lower doses or placebo, suggesting a potential benefit in slowing disease progression.

For individuals with early-stage Parkinson's, this study suggests that CoQ10 might help slow the worsening of symptoms, particularly at higher doses. This could mean a longer period of better functioning before requiring more intensive treatments.

As a Phase II randomized controlled trial published in a reputable journal, this study provides moderately strong evidence. However, the authors note that larger studies are needed to confirm these findings, so it should be interpreted with cautious optimism.